SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles

[May 02, 2014]

Research and Markets: Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/7ndsd4/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA andR&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products


Companies Involved in Therapeutics Development

  • Johnson & Johnson
  • Aradigm Corporation
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Arena Pharmaceuticals, Inc.
  • Targacept, Inc.
  • Invion Limited
  • Marinus Pharmaceuticals, Inc.
  • Royalty Pharma
  • Selecta Biosciences, Inc.
  • Embera NeuroTherapeutics, Inc.
  • NAL Pharmaceuticals Ltd.
  • BIOPROJET SCR
  • Astraea Therapeutics, LLC
  • Adial Pharmaceuticals, LLC
  • Istituto Italiano di Tecnologia

Drug Profiles

  • GSK-598809
  • lorcaserin hydrochloride
  • nadolol
  • ganaxolone
  • cycloserine
  • BP-1.4979
  • meclizine hydrochloride
  • zonisamide
  • ARD-1600
  • (oxazepam + metyrapone)
  • ondansetron
  • SEL-068
  • PF-05402536
  • PF-06413367
  • cycloserine
  • Small Molecule for Smoking Cessation
  • nicotine
  • NIC7-DT
  • CC-4
  • Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation
  • Small Molecule for Smoking Cessation
  • Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking Cessation
  • Small Molecules to Inhibit FAAH for CNS Disorders
  • Nicotine Vaccine
  • NAL-2762

For more information visit http://www.researchandmarkets.com/research/7ndsd4/smoking_cessation


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy